At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Guanfacine XR 3mgs/daily +1 moredrug
Likely dose
Guanfacine XR 3mgs/daily 3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)
In Brief
A Phase 2 clinical trial evaluating Guanfacine XR 3mgs/daily and Placebo (for guanfacine) for Alcohol Abstinence. Completed, enrolled 32 participants across 1 site.
Detailed Summary
Guanfacine may preferentially reduce craving and improve cognitive control in women with Alcohol Use Disorder (AUD), compared to men. As these behaviors are related to relapse, the objectives of this study are to conduct a 10-week out-patient clinical trial to examine the effects of Guanfacine Extended Release (XR; 3mgs) versus placebo on drinking measures in women with AUD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Abstinence
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartJul 2017
Primary CompletionMar 2021
TodayJul 2026
First PostedMay 2, 2017
Enrollment StartJul 12, 2017
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.2 years ago
Interventions
Guanfacine XR 3mgs/dailydrug
Guanfacine 3mg tablet
Placebo (for guanfacine)drug
Sugar pill manufactured to mimic guanfacine tablets